Page last updated: 2024-08-22

helenalin and Acute Myelogenous Leukemia

helenalin has been researched along with Acute Myelogenous Leukemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Abdel Ghani, L; Dörner, W; Frank, D; Harki, DA; Khandanpour, C; Klempnauer, KH; Moorthy, R; Widen, JC; Yusenko, MV1
Berdel, WE; Coulibaly, A; Jakobs, A; Klempnauer, KH; Müller-Tidow, C; Schlenke, P; Schmidt, TJ; Schomburg, C; Steinmann, S; Uttarkar, S1

Other Studies

2 other study(ies) available for helenalin and Acute Myelogenous Leukemia

ArticleYear
A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells.
    Cancer letters, 2022, 04-01, Volume: 530

    Topics: 3T3 Cells; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Cell Line; Cell Line, Tumor; Gene Expression Regulation; HEK293 Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Ligands; Mice; Mice, Inbred C57BL; Promoter Regions, Genetic; Sesquiterpenes, Guaiane; THP-1 Cells; Transcriptional Activation

2022
An isoform-specific C/EBPβ inhibitor targets acute myeloid leukemia cells.
    Leukemia, 2016, Volume: 30, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Protein Isoforms; Sesquiterpenes; Sesquiterpenes, Guaiane

2016